Skip to content
SentinelMarket desk
Switch to dark mode

신라젠

215600KOSDAQView the 바이오 R&D sectorTheme Bio & healthcare

2,240KRWMarket close of 10/21 (Wed)

Up +0.90%+20KRWMarket close of 10/21 (Wed)

Preliminary value right after the close — replaced by official KRX data tomorrow morningClose of 10/22 (Thu)2,220KRWDown -0.89%

Preliminary · just after the close · replaced by official KRX data tomorrow morning

Open
2,210
High
2,285
Low
2,210
Day range
Day range low 2,210 high 2,285, open 2,210, close 2,240, previous close 2,220
Volume
20×10K shares
456.04 million KRW 0.40× the 20-session average

Market close of 10/21 (Wed)

Where it sits in the 1-year range

1-year close range 1,844 to 4,975 won, 13% up from the low

13% of the way up from the lowest close in 1 year (252 sessions) · -55.0% from the high

Something to check

1 to check: operating loss

Free · no sign-inSource from 2021-05-17

Points to check

  • Earningsto check-26.1B KRWOperating income over the last four quarters -26.1B KRW (loss)Operating income, 8 quarters
  • Recent filingsnot verifiedOutside filing data coverage, so not verified
  • Foreign & institutionalnot verifiedOutside investor-flow coverage, so not verified

The other 3 are within the usual range

  • Daily move+0.90%usual range
  • Trading value0.4×usual range
  • Data date10/21 (Wed)Market close
See the full check report

Quarterly results · Q1 2026

Source: DART financials (Q4 derived as annual − three quarters) · Amended filing reflected
  • Revenue2.9B KRWRevenue bars for the last 8 quarters; the dark bar is this quarter
    vs. year ago
    +146.4%
    vs. prior quarter
    -2.1%
  • Operating income-5.6B KRWOperating income bars for the last 8 quarters; the dark bar is this quarter
    vs. year ago
    Still a loss
    vs. prior quarter
    Still a loss
  • Operating margin-198.1%Operating margin bars for the last 8 quarters; the dark bar is this quarter
    vs. year ago
    +243.0 pp
    vs. prior quarter
    +82.1 pp

Quarterly operating income trend

As of the latest official close · 2026-10-21Valuation filing date · 2026-08-14
2021Q1 -4.2B KRW2026Q1 -5.6B KRWQ4 values are derived as the annual figure minus Q1–Q3. The value table marks them in the Type column.

Same sector · 바이오 R&D

Up +3.03%

· 33 of 64 stocks up, preferred shares excluded · trading value 215.2B KRW

Same sector · top by trading value
Stock20DChangeTrading value
알테오젠Close over the last 20 sessions -5.5%Up +3.90%60.7B KRW
올릭스Close over the last 20 sessions -6.4%Up +9.53%26.1B KRW
디앤디파마텍Close over the last 20 sessions -6.0%Up +6.65%22.0B KRW
리가켐바이오Close over the last 20 sessions -14.3%Up +2.00%12.9B KRW
프로티나Close over the last 20 sessions +35.7%Up +7.23%11.0B KRW

Schedule

  • Next data 10/23 (Fri) after 08:50

Investor flows, financials and valuation are provided for 369 stocks. These stocks account for about 85% of trading value, about 92% of market capitalisation. Coverage status →

For information only, not a solicitation to invest. Investment decisions and their results are your own responsibility.